Get caught up quickly on the top news and calls moving stocks with these Top Fives, as compiled by the editors of The Fly.

1. STOCK NEWS:

• The CDC confirmed the first U.S. omicron variant case in California [more]
• Salesforce (CRM) provided a "beat and raise" report for Q3 [more]
• Exxon Mobil (XOM) will maintain capital investments of $20B-$25B through 2027 [more]
• HP Enterprise (HPE) reported upbeat Q4 results [more]
• The FDA's Antimicrobial Drugs Advisory Committee voted to recommend Merck (MRK) and Ridgeback's COVID antiviral drug [more] 

2. WALL STREET CALLS: 

• Krispy Kreme (DNUT) downgraded to Sell from Neutral at Goldman Sachs [more]
• Gordon Haskett sees "compelling re-entry point," upgrades DoorDash (DASH) to Buy [more]
• Capital One (COF) upgraded to Neutral after underperformance at Baird [more]
• D.R. Horton (DHI) downgraded to Neutral from Buy at Goldman Sachs [more]
• Lennar (LEN) upgraded to Buy from Neutral at Goldman Sachs [more]

3. AROUND THE WEB:

• MLB's Oakland A's looking at Bally's (BALY) Tropicana in Las Vegas to build stadium, CNBC reports [more]
• Saint-Gobain among suitors eyeing GCP Applied Technologies (GCP), Bloomberg says [more]
• A Skechers (SKX) investor is calling for changes to raise the company's value, Bloomberg says [more]
• Moderna (MRNA) said it could have an omicron booster ready by March, Reuters reports [more]
• AstraZeneca (AZN) dropped its plan to test a COVID-19 booster in the U.S., Bloomberg reports [more]

4. MOVERS:

• Arbutus Biopharma (ABUS) jumps after Moderna (MRNA) denied appeal in drug delivery patent fight [more]
• Johnson & Johnson (JNJ) rises after the FDA announced the approval of J&J's daratumumab plus hyaluronidase-fihj and Amgen's (AMGN) carfilzomib plus dexamethasone [more]
• Build-A-Bear (BBW) and G-III Apparel (GIII) higher after reporting quarterly results [more]
• BeyondSpring (BYSI) falls after the FDA determined that the plinabulin NDA cannot be approved in its present form [more]
• CTI BioPharma (CTIC) lower after announcing the FDA has extended the review period for the new drug application for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis [more]

5. EARNINGS/GUIDANCE:

• Allbirds (BIRD) slips after first report since coming public [more]
• Box (BOX) reported upbeat Q3 results and expanded its stock buyback program [more]
• GlobalFoundries (GFS) reported what Morgan Stanley called a "solid" first report since coming public [more]
• Ambarella (AMBA) reported upbeat Q3 results [more]
• Zscaler (ZS) reported upbeat Q1 earnings and revenue [more]

INDEXES:

The Dow fell 461.68, or 1.34%, to 34,022.04, the Nasdaq lost 283.64, or 1.83%, to 15,254.05, and the S&P 500 declined 53.96, or 1.18%, to 4,513.04.